Analysis of the expression changes of IL-17+ γδ T cells and Treg cells in bone marrow mesenchymal stem cells targeted therapy for allergic rhinitis

B. Zou, R.-X. Zhuang, X.-Y. Sun, J. Liang

Department of Otorhinolaryngology, Children’s Hospital of Chongqing Medical University, Chongqing, China; National Clinical Research Center for Child Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Children’s Hospital of Chongqing Medical University, Chongqing, China; Chongqing Key Laboratory of Pediatrics, Chongqing, China. zoubin@hospital.cqmu.edu.cn

---

• Otorhinolaryngology

OBJECTIVE: Bone marrow mesenchymal stem cells (BMSCs) have immunomodulatory and therapeutic effects on immune system diseases. This study intends to assess the regulatory effect of BMSC targeted therapy on the IL-17+ γδ T cells and Treg cells in allergic rhinitis (AR).

MATERIALS AND METHODS: BALB/c mice were sensitized by ovalbumin (OVA), while BMSCs were injected intravenously before sensitization and followed by an analysis of nasal symptoms, inflammation, cytokines, and immunoglobulins. BMSCs were co-cultured with peripheral blood mononuclear cells for 3 days to test Foxp3+ expression, IL-17+ γδ T and Foxp3+Treg cell ratio, and cytokines secretion.

RESULTS: After intranasal administration of BMSCs, nasal symptoms and inflammatory infiltration in mice were significantly alleviated, accompanied by reduced OVA-specific IgE in serum. BMSCs significantly inhibited the activity of T lymphocytes, increased TGF-β1 level, decreased IL-17A level, promoted Treg proliferation, and suppressed the proliferation of IL-17+ γδ T cells.

CONCLUSIONS: BMSC targeted therapy can be used to treat AR by regulating Treg cells to correct IL-17+γδ T cell immune imbalance and is expected to be an effective treatment method for AR.

Free PDF Download